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Abstract
This project aims to design and develop a robust diagnostic intravascular imaging system
for in situ detection of labeled coronary vulnerable plaques, consisting in the integration
of targeted nano-probes with a novel protocol for IV-OCT (Intravascular optical coherence
tomography) imaging, to analyze anatomical and molecular features of plaques with high
precision, sensitivity and specificity.
This approach to molecular imaging using IV-OCT focuses primarily in the inves-
tigation of possible contrast agents. Thus, this study is composed, in addition to their
functionalization, by the comparison of gold nanostars and Poly(n-butyl cyanoacrylate)
(PBCA) microbubbles as possible candidates. The results show a special attention to
PBCA microbbubles being that they exhibited the most noticeable scattering e↵ect lead-
ing to more valuable imaging.
A three-dimensional structured tissue-mimicking phantom was also presented for
use in IV-OCT. The phantom was fabricated from a PDMS matrix and titanium dioxide
additive, capable of producing a wide variety of scattering densities. We describe the
fabrication, characterization and IV-OCT imaging of these phantoms and demonstrate
their utility in functionalization with two types of contrast agents.
Finally, commercial Endothelium-targeted PBCA microbubbles (Fujifilm Visualson-
ics) were tested using clinical IV-OCT systems in post mortem human arteries allowing its
unequivocal location in the sample. The results present the first steps towards adding to
the routinely used IV-OCT a new functionality.
Dissertation goals: Contrast agent-aided molecular imaging process. The direct visual-
ization of endogenous disease markers in the body is nonexistent as it is not possible to
distinguish from surrounding tissue using OCT imaging. The proposed method rests in
the use of exogenous contrast agents with the specificity to bind to the target in question.
Image designed in Adobe Illustrator®.
Keywords: Gold nanoparticles, Molecular Imaging of atherosclerosis, Nanotechnology,
OCT intravascular imaging, PBCA microbubbles, Targeted nano-probes.
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Resumo
Este projeto tem como objetivo delinear e desenvolver um sistema robusto de diagnóstico
por imagem intravascular para a deteção in situ de placas coronárias vulneráveis, que
consiste na integração de nano-sondas endereçadas a bio-marcadores característicos da
doença com um novo protocolo de imagem intravascular por tomografia de coerência
ótica (IV-OCT). Conseguindo assim analisar características anatómicas e moleculares das
placas com alta precisão, sensibilidade e especificidade.
Esta abordagem de imagem molecular usando IV-OCT concentra-se principalmente
na investigação de possíveis agentes de contraste. Assim, este estudo é composto, para
além sua funcionalização, na comparação de nanoestrelas de ouro e microbolhas de poli(n-
butil cianoacrilato) (PBCA) como possíveis candidatos. Os resultados apresentam as mi-
crobolhas de PBCA em foco, dado que estas exibem um efeito de dispersão mais perceptí-
vel, levando a imagens mais valiosas.
É importante salientar que um simulador físico de tecidos biológicos (Phantom) foi
igualmente apresentado para uso em IV-OCT. Este material, criado para mimetizar algu-
mas das propriedades óticas das artérias humanas, foi fabricado a partir de uma matriz
de polidimetilsiloxano (PDMS) na qual foram dispersas nanopartículas de dióxido de
titânio, sendo possível obter uma ampla variedade de densidades de espalhamento da luz.
A fabricação, caracterização e imagem por OCT dos referidos phantoms é descrita, bem
como a demonstração da sua utilidade na funcionalização com dois tipos de agentes de
contraste.
Por fim, destaca-se que microbolhas de PBCA comerciais (Fujifilm Visualsonics) foram
funcionalizadas com anticorpos contra células endoteliais e testadas usando sistemas clí-
nicos de OCT em artérias humanas post mortem, permitindo a sua localização inequívoca
na amostra. Os resultados apresentam os primeiros passos em direção a acrescentar uma
funcionalidade extra ao IV-OCT utilizado rotineiramente na cardiologia intervencional.
Palavras-chave: Imagem Intravascular de OCT, Imagem Molecular de Aterosclerose, Mi-
crobolhas de PBCA, Nano-sondas direcionadas, Nanopartículas de Ouro, Nanotecnologia,
Simuladores de tecido.
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Motivation and Objectives
Cardiovascular diseases (CVDs), the leading causes of death in the western world, are
now gaining ground also in developing countries [1] . Enormous e↵orts are being put
into raising awareness, research and treatment of the spectrum of CVDs, including acute
coronary syndromes (ACS) and stroke. A study by the World Health Organization, the
World Heart Federation and the World Stroke Organization into Cardiovascular Disease
Prevention and Control state that: “from the two-thirds of all deaths in the world, which
belong to non-communicable diseases, almost 50 % are from CVDs alone” [2] . Further-
more, CVDs should not only be recognized as a significant cause of morbidity but also as
a major economic burden and an obstacle to global development and sustainability[3].
Although our knowledge of disease progression leading to plaque build-up in atheroscle-
rosis has increased over the last few years, our ability to predict future events is still insuf-
ficient. Di↵erent imaging technologies are being developed to visualize various features
of vessel walls that could indicate the onset of acute cases such as ACS and stroke, but
there is yet no single technique that provides a robust prognosis of CVDs [4].
In this context, Optical Coherence Tomography (OCT) has rapidly evolved from its
initial ophthalmological applications into a plethora of medical fields, like interventional
cardiology. Since its development in 1991, at the Department of Electrical Engineering
Computer Science on the Massachusetts Institute of Technology (MIT) [5], the many
advances in OCT not only strengthened the vast applicability of the technology, but also
continue to bring enthusiasm to applications that may still be discovered. Considering
that OCT is a minimally invasive imaging method upholding high penetration depth and
spatial resolution, when compared to other imaging techniques [6].
Due to the technological shift in 2003 from the nowadays-called time-domain OCT to
the fourier-domain, the rapid imaging of the intervascular medium was finally attainable
and several clinically approved imaging systems have appeared soon after. Nevertheless,
with all the many advances, OCT still has room for innovations, not only on hardware
but also in software and optical systems. Other techniques can be implemented in the
same system, providing multidimensional information to the OCT data. For instance,
recent techniques such as Doppler [7] and Polarization sensitivity OCT [8] have brought
additional contrast to clinical images and the ability to visualize and quantify blood flow;
while supercontinuum fiber laser sources are being used to obtain high-resolution images
[9] and computational adaptive optics where suggested as the algorithm of choice for an
improved aberration correction [10].
However, a clear and unmet clinical need remains: the identification of metabolic
changes in the tissue. Despite OCT significance in the diagnosis of clinically important
diseases and unprecedented resolution of vessel microstructural features, imaging of
disease biomarkers is still elusive. OCT is foremost a morphology imaging technique and
many diseases do not promote a significant change in the tissue so the OCT can observe.
Therefore, to visualise these morphological alterations, it is necessary the use of contrast
agents. However, trough the best of our knowledge, there are no contrast agents that
can couple OCT contrast with biological targeting [11], and thus, there are no clinical
xxv
MOTIVATION AND OBJECTIVES
approaches to image disease biomarkers in biological processes using this technology.
This project fits in this contest to improve current diagnostic capabilities of intervascular
OCT as a clinical tool. We proposed to attain that goal combining OCT with molecular
imaging. Thus, the specific objectives of this work were:
• Synthesis and characterization of contrast agents able to produce significant OCT
signal;
• Optimization and development of a tissue simulating platform for rapid testing of
contrast agents;
• Synthesis of functionalized nano-probes for targeting arteries;
• Integration of targeted nano-probes with IV-OCT imaging, in an innovative protocol
to analyse anatomical and molecular features within post mortem human arteries.
In addition to putting into practice the hard skills learned during the course of Micro
and Nanotechnologies, this work greatly influenced the development of soft skills that
helped substantially in the di↵erent practical aspects of this thesis. Namely in designing
user interfaces, optimizing graphical outputs, and delivering specific data analysis tools
using MATLAB programming language, complemented with custom designed illustra-
tions/pictograms using the vector graphics editor (Adobe Illustrator®).
xxvi
Chapter 1
Introduction
1.1 Overview of atherosclerosis
Cardiovascular disease (CVD) is a generic term applied to a large number of conditions
a↵ecting both the heart and blood vessels. It is the leading cause of death in the world
and continues to be a significant burden for all society [1]. It mainly includes coronary
heart diseases (blood vessels supplying the heart muscle), cerebrovascular diseases (blood
vessels supplying the brain) and peripheral arterial diseases (blood vessels supplying
the arms and legs). Above all, the most common reason for all these disorders is the
build-up of fat deposits inside of the artery walls, a process referred to as atherosclerosis
(Figure 1.1).
Figure 1.1: Atherosclerotic plaque development. The monocytes can adhere and pass
through the endothelium, where they transform into macrophages and ingest the for-
eigner low-density lipoproteins, becoming foam cells that contribute to the narrowing of
blood vessels (Retrieved from Ref [12]).
At the beginning of the atherogenic process, patches of arterial endothelial cells begin to
express on their surface selective adhesion molecules [e.g.: selectin, vascular cell adhesion
molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) [12]] that bind
with various classes of leukocytes. This cell dysfunction process does not occur naturally,
it is a response to lesions on the endothelium wall at predisposed regions (e.g. near
branch points and along the inner curvature of the arteries) [12] due to risk factors such as
hypertension, smoking and high cholesterol level. At these sites, low-density lipoproteins
(LDLs) go through the endothelium and promote an inflammatory response that leads to
endothelial dysfunction. Once adhered to the endothelium, the leukocytes penetrate the
1
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intima (innermost layer of the artery) and di↵erentiate into macrophages that scavenge
for the foreigner LDLs. However, once the macrophages uptake reaches a limit point, the
inflammatory process no longer remains under control and a chronic process takes place.
Macrophages with an excess intake of lipids turn into “foam cells” and agglomerate
in the interior of the vessel walls, forming an atheroma or plaque. These plaques are
the basis for the atherosclerotic process and lead to the narrowing of the blood vessels
(stenosis). Although atherosclerosis on its own is rarely fatal, the rupture and thrombosis
of the atheroma account for all the acute cases such as heart attacks and strokes. The
assessment of these vulnerable plaques, that have a high risk of rupturing, remains a
challenge in cardiology [4] . After all, these plaques are mainly diagnosed accounting the
morphology of the vessel walls (i.e. high luminal stenosis and thin cap). However, it is
acknowledged that the risk of rupture depends more on the plaque composition rather
than its anatomy [4].
1.2 Current diagnosis methods
It is impossible to proclaim that a perfect imaging solution exists since it is not guar-
anteed that it will be optimal in every diagnostic situation. Di↵erent systems perform
optimally in di↵erent types of clinical practice settings. As so, several criteria are consid-
ered when comparing alternative imaging methods for plaque characterization - namely,
the resolution, imaging depth and sample intrusiveness (Figure 1.2).
The following sections will overview OCT in cardiology, comparing with other tech-
niques and finally the basic principles of this imaging method.
Figure 1.2: Comparison between di↵erent imaging techniques in terms of imaging depth
and resolution. Retrieved from the website of the Optical and Biomedical Engineering
Laboratory,"Introduction to OCT", University of Western Australia.
1.2.1 Currently used methods in cardiovascular diseases
In the diagnosis of coronary heart disease, the first common approach for the medical
doctor is coronary angiography [4]. This exam detects sites of luminal stenosis for fur-
ther treatment such as stent placement using an intravascular contrast agent and X-ray
imaging. Angiography is used primarily to localise the region where there is a blood
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flow blockage, however, it does not have enough resolution to visualize specific structures
in the artery wall. In this sense, Optical coherence tomography (OCT) has been a very
promising imaging solution in distinguishing the composition of plaque structures, fit-
ting between conventional optical microscopy (confocal and fluorescent microscopy) and
ultrasound (Figure 1.2) [6]. Whereas methods such as magnetic resonance imaging (MRI)
and intravascular ultrasound achieve greater imaging depths, allowing the diagnosis of
larger areas, OCT far exceeds in terms of resolution. A typical OCT allows for spatial
resolution up to 10µm [6], and its ability to perform in vivo images is greatly appreciated.
In the case of cardiovascular imaging, a catheter-based OCT works as a minimally evasive
solution, allowing the detailed visualization of the arterial layers and the accurate assess-
ment of plaque features in small arteries (0.5 to 1.5 mm) [13]. As so, IV-OCT has proven
to be a promising imaging modality in obtaining cross-sectional tomographic vascular
images [14].
1.2.2 Principles of OCT
The imaging process in OCT can be viewed as the light equivalent of ultrasound, measur-
ing the “echoes” of light backscattered by the sample to build an image. In intravascular
OCT (IV-OCT), a fibre optics cable (catheter) transmits the light and collects the reflec-
tion inside an artery, while rotated and pulled across its length. There are two main
approaches to obtain OCT data: time-domain and Fourier-domain methods. Originally,
OCT was developed as an interferometric technology where the spatial information was
obtained depending on the time delay between the sample and a reference beam. As so, a
very basic OCT setup, depicted in Figure 1.3, closely resembled a Michelson interferome-
ter.
Figure 1.3: Depiction of the basic interferometric OCT setup. Catheter scheme and
positioning within a sample. Image designed in Adobe Illustrator®.
The Michelson interferometer is a common configuration for optical interferometry. A
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beam splitter divides the light beam emitted from a light source, so that half goes into a
reference path (mirror) and the other half to the sample. The beams are reflected back
in both arms of the interferometer and recombined before being detected by a sensor,
producing an interference e↵ect.
Figure 1.4: OCT scan Types. A-scan,
B-scan, tomographic reconstruction
(3D reconstruction and sectioning).
Image designed in Adobe Illustra-
tor®.
However, it is essential to note that this interfer-
ence, meaning constructive/destructive interaction
between the two light beams, only occurs when the
optical path on both arms of the interferometer is
almost equal (di↵erence smaller than the coherence
length of the light source). Thus, by moving the
reference arm, the location of a certain feature in
the sample can be assessed with the resolution of
the coherent length of the source. Moreover, a inter-
ference pattern is obtained depending on the mir-
ror position, corresponding to the specific reflection
characteristics of a feature in the sample at that po-
sition (optical path distance).
Performing a pre-determined sweep of the refer-
ence mirror positions, which correspond to an imag-
ing depth range, one axial (Z) scan is obtained. This
is also referred to as an amplitude scan (A-scan) and
corresponds to a map of the di↵erent reflections
within one axial direction (Figure 1.4). Addition-
ally, it is possible to obtain a cross-section of the
sample by joining multiple A-scans from directions
transverse to the light beam (B-scan). Finally, by
combining multiple B-scans a 3D model of the sam-
ple is attained.
It is important to note that the coherence length
of the light source (lc) determines the axial reso-
lution. Oversimplifying, the coherence length de-
scribes the distance over which two beams main-
tain a constant phase di↵erence hence interference
is observed between these two beams. For this
reason, broadband light sources, which have low-
coherence, are used to better di↵erentiate the reflec-
tions from individual structures in the path of the
beam.
However, in 2003, di↵erent studies have demonstrated that the shifting from Time-
domain methodology to Fourier-Domain improved the detection sensitivity by several
orders of magnitude [15]. As so, current devices no longer use the conventional OCT
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setup, they obtain measurements in the frequency space, though the same principle of
interferometry remains. In Fourier-Domain OCT (FD-OCT) the reference arm of the
system is fixed and the measurements are wavelength-dependent. In general terms, the
intensity of light hitting the detector (I) that defines the OCT output signal is given in
terms of the resulting electric field, E, in equation 1.1 [16].
I ⇡ cn"0
2
|E|2 (1.1)
Where c is the speed of light in vacuum, n is the refractive index of the medium and
"0 the vacuum permittivity. Nevertheless, the resulting electric field, E, corresponds to
an interaction between the electrical component of the optical field from the sample arm
(Es) and the electrical component from the reference arm (Er ), in the form(1.2):
|E|2 = |Es |2 + |Er |2 + 2 |Es | |Er |cos(!⌧) (1.2)
Where ! corresponds to the source optical frequency and ⌧ to the delay caused by the
optical path di↵erence between the sample and the reference arms. In the Time-domain
OCT, the frequency ! is fixed and the ⌧ changes with the movement of the reference
mirror. The cosine term then yields a maximum received signal when ⌧ = 0, i.e., the
optical path distance di↵erence between the reference and sample arms is zero. As long
as the movement of the mirror is known (position ⇥ time), interferograms such as the
one observed in Figure 1.3, of the light intensity versus mirror displacement I(⌧), can
be obtained. In contrast, the Fourier-Domain OCT fixes the reference mirror position,
maintaining the optical path di↵erence constant and measuring the intensity spectrum in
the frequency domain I(!), which is then converted to a measurement equivalent to the
Time-Domain using the inverse Fourier transform. A detailed discussion of the numer-
ous practical aspects of optical coherence tomography and mathematical formulations
is beyond the scope of this work. Additional information on this topic can be found in
pertinent works already reported [16–18].
1.3 How tissue material appears in OCT
In OCT, light from the source is attenuated (scattered and absorbed) as it passes through
the tissue sample. The strength of backscattering, the main imaging process in OCT,
provides a mechanism to di↵erentiate structures and is influenced by the di↵erent con-
stituents in the biological medium (cells, organelles and fibres) [19]. Absorption, on the
other hand, occurs mainly in pigments, such as haemoglobin and melanin and water [20].
It limits on how much the OCT can measure, and it depends on the source wavelength
and the tissue characteristics. Therefore it is important to note that, in order to achieve
greater imaging depths in tissues, absorption must be the lowest possible (ignoring scat-
tering e↵ects). Therefore, as di↵erent biomolecules absorb certain wavelengths more
readily than others do, a diagnostic/therapeutic spectral window is always defined when
working with light-tissue interactions [21]. Light at wavelengths in the near-infrared
(NIR) spectral region, from 1100 to 1350 nm, correspond to low blood absorption (oxy-
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and deoxyhemoglobin) [21]. To this end, the central wavelength of the IV-OCT light
source is generally chosen in the range of 1250 to 1350 nm [22] . Moreover, the size,
shape, density of di↵erent scattering structures and their refractive index predetermine
the character of light propagating in tissues. Allowing for a morphologic assessment of
the interior of vessel walls and a preliminary study of their composition.
1.4 OCT perspectives
As referred, plaque vulnerability seems to depend more in composition than morphology.
As a result, diagnosis with OCT falls short due to the inability of detecting distinctive
biological traits, such as disease chemical markers. The ideal imaging method should
report not only the volume of plaques within the artery walls but also plaque biologi-
cal characteristics. Thus, to enhance the capability of this imaging system would be to
combine OCT with molecular imaging. This hybrid optical imaging approach exploiting
the high-resolution and excellent penetration depth of OCT with a smart optical con-
trast agent could dramatically enhance imaging capabilities. A contrast agent that can
elicit molecular contrast grants the possibility of tracking the distribution of biochemical
components in samples [23]. Thus, allowing trailing diseases evolution in patients and
trial subjects. There are two ways by which molecular contrast–based OCT (MCOCT)
procedures can be utilized to image a particular chemical or protein distribution within
a target:
• Directly detecting the chemical or protein due to its innate contrast capabilities;
• Attaching a contrast agent to a vehicle that recognizes and binds to the chemical or
protein in question.
In the work of Yang et al. [24], an example of this first method is presented (Direct
detection). The distribution of a plant protein (phytochrome A) is achieved from pairs
of consecutive OCT A-scans. This specific protein can reversibly switch between two
states with di↵erent absorption maxima accordingly to the wavelength of an externally
exposed light. In this type of technique, the contrast agent is endogenous to the target
organism. However, it is not very often that we find the required protein or chemical that
also performs well as a contrast agent. Moreover, even if in principle it should be possible
to genetically-engineer animal models to express these proteins for biomedical research
applications, simpler and quicker diagnosis methods are required.
For the second method presented of MCOCT imaging, the molecular target is high-
lighted by what we can refer has marker “buoys”. An exogenous contrast agent that is
e ciently distinguished by the OCT can be functionalized so that it ties to the particular
chemical or protein of interest. As a figure of speech, imagine a diver as an antibody that
finds and binds to the wanted protein (Treasure) (Figure 1). Attached to him is the buoy
that pops up on the water surface, warning the boats that a diver will soon float. The
only detectable signal by means of OCT is the buoy, from which by now the position can
be used to co-localize both the diver and the protein sought for. This method has a very
significant advantage, since it can be used to recognize and map chemicals or protein that
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are otherwise undetectable directly by OCT in the target tissue, as long as it is possible
to design a contrast agent that is visible in the OCT system.
1.5 Molecular contrast agents: Micro and nanoparticles
Optical molecular imaging is rapidly expanding using new exogenous molecular probes
[25]. Di↵erent types of contrast agents are being studied for OCT [4], however, mainly
four categories apply: scattering, modulating, absorbing and plasmon resonant probes.
For the first category, scattering, the most common particles are metals and other particles
with a refractive index significantly di↵erent from the tissue. Scattering is an optical
phenomenon that depends on size of the particles and the wavelength of the light (as
the case of Raleigh and Mie scattering), but it generally increases with the magnitude
of the refractive index di↵erence between the particle and the surrounding media. The
microbubbles studied in this work are an example of this category.
Since OCT detects light backscattered from refractive index mismatches it was fore-
casted that gas-filled microbubbles would produce contrast in OCT. In fact, the first
study of the e↵ects of microbubbles was presented in 2002 by Barton et al. [26]. Initial
tests in phantoms demonstrated that MB can be used as contrast agents for OCT [26].
Since the microbubbles increased the attenuation coe cient of blood a great advantage
in the use of MB arised and became the main focus of such contrast agents. The enhanced
visualization of the blood vessel lumen, because after all the optical properties of blood
are very similar to the surrounding tissue [26].
More recently studies have focused on the quantitative assessment of the MB contrast
in well-controlled systems that accurately mimic tissue optical properties and flow con-
ditions [27]. However, the study of targeted imaging using MB in OCT has been lacking.
While microbubbles are being readily used with ultrasound systems to the point that
there are already FDA approved commercial contrast agents.
In the second case, modulating probes modify one observable property in situ, like
the case of the plant protein presented by Yang et al. [24]. While background remains
constant, the alternation between di↵erent observable states allows for an improved
detection. Which, in this case, depends mostly on the comparison of two consecutive
images. The absorbing probes case is based on the local attenuation due to absorption
[25]. Instead of focusing in the local optical changes, the e↵ect of absorbing probes is
noticed in deeper structures of the tissue, as reduced backscattering intensity is observed
in these regions. In this case, the contrast agent promotes a shadow e↵ect, as it absorbs
most of the light passing through, structures that are behind it do not receive enough
light to be visualised. Finally, plasmon-resonant probes address the trend of reducing
the size of the probes while maintaining a su cient scattering cross section. This is
accomplished by the use of metal nanoparticles that exhibit a phenomenon called surface
plasmon resonance (SPR). The collective excitation of electrons promotes an increased
scatter e↵ect in the nanoparticles, and it depends on the material, size, and structure of
the particle.
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Materials and Methods
Additional information and the detailed protocols regarding this section can be consulted
in Annex I and II.
2.1 Synthesis and Characterization of the contrast agents
2.1.1 Gold Nanostars (GNST)
The detailed protocol on all the steps for the synthesis of gold nanostars can be found in
annex I. Gold nanostars were synthesised using a method modified by the microfluidics
group at INL, of a previously reported seed-mediated growth by Pandian Senthil Kumar
et al [28]. Already synthesised, citrate stabilized 15 nm spherical gold nanoparticles,
produced with the Turkevich method [29] were previously coated with polyvinylpyrroli-
done (PVP) and used as gold seeds for the following GNST synthesis (Au@citrate@PVP
- 2⇥ 10 3 M). For the typical seed-mediated growth, 2.5 g of polyvinylpyrrolidone (PVP
MW = 10,000 g mol 1) were dissolved in 25 mL of N, N’-dimethylformamide (DMF,
MW= 73.09 g mol 1), using an ultrasound sonicator, until all was dissolved. Following,
99.15 µL of an aqueous solution of chloroauric acid (HAuCl4 - 0.1268 M) was added
to the solution under magnetic stirring. During the 1 min of mixing, the solution got
lighter in colour from the reduction of Au3+ to Au1+. Following, 317 µL of Au@PVP
seeds (2⇥ 10 3 M) were quickly added to the solution still under stirring. The reaction
flask was left covered with aluminium foil to protect it from light. Within 2 h, the color
of the solution changed from brownish to a very dark blue/grey, indicating the formation
of gold nanostars in solution. The resulting gold nanostars were washed (5500 rpm, 60
min) with IPA to stop the reaction and remove excess reactants.
To prepare codified gold nanostars, 4 µL of ammonium hydroxide (NH4OH- 29%), 2
µL of an ethanol solution of mercaptoundecanoic acid (MUA – 3.75 mM) and di↵erent
fluorescence dyes (10 4 M) were added to 2 mL Eppendorf’s containing 0.8 mL of a 1
mM solution of the previously synthesised gold nanostars. Although only one of the
fluorescence dye was used in the further experiments (Nile Blue - NB), di↵erent batches
of GNSTs were also coded with toluidine blue (TB). After continuous magnetic stirring
for 2 hours, each one of the solutions passed through 2 washing steps composed of an
ultrasound bath for 2 min and centrifuge at 2500 rpm for 30 min. Each time re-dispersing
in IPA until 1 mL. The resultant gold nanostars where characterized using a FEI Quanta
650 FEG scanning electron microscope and further absorbance measurements were taken
in a Perkin-Elmer LAMBDA 950 UV-VIS-NIR Spectrophotometer. The size distribution
was preformed using the imaging processing package Fiji for ImageJ.
2.1.2 PBCA microbubbles
Poly(n-butyl cyanoacrylate) (PBCA) microbubbles where kindly provided by Prof. Twan
Lammers’ (ExMI, Helmholtz Institute for Biomedical Engineering - Germany) group. Two
di↵erent varieties of PBCA microbubbles where received. Initially, PBCA microbubbles
where obtained in Triton-X without any surface active groups. This microbubbles varied
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in size from 1.8 to 2.5µm and where produced in professor Twan lammers group [30].
The second batch consisted of VeVo MicroMarker® Target-Ready contrast agents (from
Fujifilm Visualsonics) made by Bracco Research SpA. These where used for further bio-
functinalization procedures. Using the preparation protocol from Fujifilm Visualsonics,
VeVo MicroMarker® Target-Ready contrast agents were reconstituted. Initially 0.7 mL of
saline was injected into the microbubble flask with a 21G ½” needle attached to 1 mL
syringe. The syringe was then removed letting the vial vent with the needle still injected.
Finally, the needle was removed completely, and the vial gently agitated for 10 seconds.
The synthesis process of both batches can be analyzed in detail in reference [30].
2.2 Functionalization
2.2.1 Immobilization of gold nanostars on PDMS surface
The immobilization method was performed using a modification of the previously re-
ported work of Nguyen Ba Trung, et al. [31]. The formerly synthesised coded (Nile blue)
gold nanostars were deposited on a poly(dimethylsiloxane) (PDMS) substrate based on
electrostatic interactions. Substrates were first activated with oxygen plasma for 2 min.
On this step, a mask in the form of another PDMS slab or adhesive tape, was used to
cover a specific area of the substrate, in order to adhere the nanoparticles on the ex-
posed side. Following a washing step with ethanol, the substrates were dried with N2 gas.
The cleaned substrates where then immersed in di↵erent silane solutions. Initially the
silane crosslinker used was (3-Aminopropyl)trimethoxysilane (APTMS, sigma Aldrich)
at 1%(v/v) and 8.33%(v/v) ethanol solution. While in the end it was switched to (3-
Aminopropyl)triethoxysilane ( -APTES, sigma Aldrich) at 1%(v/v). The substrates where
immersed for 5 or 15 min in each of the solutions. From here on, the substrates were
immediately cleaned with ethanol and water to remove any residual silane molecules.
Then the masks were removed. Next, the samples were annealed at 80°C for 1 hour and
30 minutes. Finally, the substrates are immersed on the colloid gold nanostars solution,
previously prepared, again for 1h and 30min and thoroughly rinsed with deionized water.
The substrates are well dried and placed in the oven for an annealing step of 1 hour at
80 ºC. A Zeiss LSM780 confocal microscope with 34 simultaneous confocal fluorescence
counting channels was used to access the distribution of the coded nanoparticles.
2.2.2 Biofunctionalization
The detailed protocol of the biofunctionalization process can be found in annex II. Tissue.
-80 °C frozen human carotid was obtained for immunohistochemistry, these samples are
considered in a protocol with INMLCF (Instituto Nacional de Medicina Legal e Ciências
Forenses). The artery sections where cut crosswise into two pieces, defrosted and fixed in
acetone at -20 °C. Following, all the samples were washed three times in PBS.
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Biotin-labelling of Unconjugated Goat Anti-rabbit IgG antibody. Immunoglobulin
(IgG) molecules (Novex by Life technologies TM, Lot 62-10-092817) where first biotiny-
lated using Thermo ScientificTM EZ-Link TM Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-
6-[biotin-amido]hexanoate) (MW: 556.59 ;Lot. Nr. A39257 21335). The devised protocol
was based on the user’s guide for the EZ-Link TM product (MAN0016133, Pub. Part
No.21611855). Initially a 10 mM solution of the biotin reagent was prepared in 500µl
of ultrapure water. Following, a 60-fold molar excess of biotin (10µl) was taken from
the prepared solution and added to 3.75 mL of a saline solution containing 250µg of the
stock antibody. The solution was then incubated at room temperature for 30 min. The re-
sulting antibodies where further purified using Amicon Ultra-0.5 Centrifugal Filter units
with a Ultracel-100 regenerated cellulose membrane and a nominal molecular weight
limit of 100 k at 2000 rpm for 2 min. The protein concentration on di↵erent steps of
the filtration was obtained with a Nanodrop 2000 microvolume spectrophotometer from
Thermo Scientific.
Immunohistochemistry procedures. Primary immunohistochemistry of rabbit anti-
VE-Cadherin IgG antibodies (Thermo Fisher, Code: V1514-200UL, Lot. 016M4804V) was
performed overnight (8h) at 4°C. The primary antibody solution was prepared accord-
ing to the recommended values described by the supplier. From a PBS bu↵er solution
containing 1% of bovine serum albumin (BSA), 4 mL where mixed with 20.4µl of anti-
VE-Cadherin IgG. The positive artery samples where then immersed in this solution
and left incubating overnight. The negative samples where immersed in a PBS blocking
solution with 3% BSA and also left overnight. After this process the samples were washed
three times in PBS. The VeVo MicroMarker microbubbles where reconstituted from the
respective vial as referenced in section 2.1.2 and the preparation protocol from Fujifilm
Visualsonics was again used for further biofunctionalization. Using a 21G½” needle with
a 1 mL syringe 0.3 mL of the filtered biotinylated Goat Anti-rabbit IgG (20µg) where in-
jected into the microbubble vial (total volume of 1 mL). The functionalized contrast agent
solution was then gently agitated by hand for 1 min and left to rest at room temperature
for 15 minutes.
The secondary immunohistochemistry step was finally performed by transferring the
fully assembled microbubble solution to an Eppendorf with the positive artery section,
adding 2 mL of saline to top the required 3 mL necessary for the experiment. Joining
the secondary antibody (Goat Anti-rabbit IgG) with the primary antibody (rabbit anti-
VE-Cadherin IgG). The incubation step was performed for 1 hour at 4°C while agitating
and was followed by three washes in PBS. The artery sections where supended in a saline
solution.
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2.3 Phantom design
2.3.1 Scattering agents
The TiO2 nanoparticle synthesis was performed in CENIMAT/i3N at NOVA University.
The hydrothermal-microwave assisted method was slightly adapted from a previously re-
ported work [32]. A CEM Discover SP Microwave Synthesiser was used for the hydrolysis
of a solution containing 2 mL of a titanium precursor (Titanium (IV) isopropoxide, sigma
Aldrich), 5 mL of an acid catalyst (Nitric acid, sigma Aldrich) and 55 mL of ethanol.
The solution was first prepared under magnetic stirring until all reactants were fully
mixed. Only then where 20 mL transferred to a Pyrex reaction vessel and placed in the
microwave synthesiser. Next a predefined program was set for 1 hour and 15 min with
the following set points: 200 ºC, 100 PSI and 100 W. Further commercial TiO2 powders
where used in later phantoms. The Characterization of the TiO2 powders was performed
on a FEI Quanta 650 FEG electron microscope.
2.3.2 PDMS nanocomposite phantoms
SYLGARD® 184, a two-part Polydimethylsiloxane (PDMS) kit from DOWSIL (formerly
DOW CORNING, Michigan, EUA) was used as the matrix material for the phantoms. The
kit is composed of a base (PDMS) and a curing agent (reactive). The PDMS phantoms
were produced in a two-step approach. First, the titanium dioxide particles with a weight
percentage of 0.6% to 3% (according to which layer) are introduced into the base resin
without the reactive. Each of the mixtures was initially hand mixed and then placed in
the ultrasounds for at least 4 h. Next, the required amount of the PDMS composite was
transferred to a separate container were the curing agent was added in a ratio of 10:1.
The final compound was mixed and poured into the moulds were each layer is left to cure
for 1 h at 65 °C. The composite material was synthesized by simple mixing, without any
treatment to both the matrix PDMS and titanium dioxide nanoparticles. It is important
to note that the compositions of the phantoms here presented were based and modified
from the article in Ref [33], which uses alumina as the scattering agent. Furthermore, as
in the work by Bisaillon et al. [33], we decided not to use anything to induce absorption
in the phantoms.
2.4 OCT
Two di↵erent clinical IV-OCT systems where used in situ, thanks to the partnership with
Dr. Victor A. Jimenez Diaz team at the Cardiology Department of Hospital Alvaro Cun-
queiro (University Hospital of Vigo, Spain) and Dr. Carlos Galvão Braga at the Cardiology
Department of Hospital de Braga (2CA-Braga, Portugal). Pullbacks from University Hos-
pital of Vigo were acquired from a Lunawave coronary imaging console with a Fastview
coronary imaging catheter (Terumo Corporation, Ashitaka, Japan), hereafter referred to
as “Terumo-OCT”. While pullbacks from Hospital de Braga were acquired using the
ILUMEN FD-OCT system from Abbott (formerly St. Jude Medical, St. Paul, MN) with a
C7 Dragonfly catheter.
12
Chapter 3
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3.1 Phantom characterization
3.1.1 Scattering agents
To introduce optical scattering, white titanium dioxide (TiO2) powders were added to the
phantoms. These were chosen as potential scattering agents for the optical phantoms as
they are a easily synthesized material and even commercially available at low-cost.
Commonly used as a whitening pigment in paint, sunscreens and even food couloring,
TiO2 powders are often used to fabricate OCT phantoms even tough their refractive index
(2.3) greatly exceeds those from most often biological structures [34]. However, in the
context of this research, the emulation of tissue optical properties was mainly oriented on
how light interacts with the phantom and not the rigorous mimicking of all the optical
properties of common tissues. As so the main concern was obtaining di↵erentmagnitudes
of scattering scales by mixing di↵erent concentrations of TiO2.
Initially a small amount of TiO2 powder was synthesised at CENIMAT/i3N using a
hydrothermal-microwave assisted method. After further development of the phantoms,
commercial food grade TiO2 was purchased. A comparison of both samples was taken
using scanning electron microscopy. The hydrothermally synthesized TiO2 exhibited
irregular morphology throughout all the sample with particles smaller in size than those
seen in the commercial powder. However, the commercial powder is composed of roughly
spherical nanoparticles with sizes ranging from 70 to 300 nm.
Figure 3.1: Scanning electron microscopy (SEM) images of the hydrothermally synthe-
sised TiO2 powders and the commercially available ones: (a) TiO2 powder synthesised at
CENIMAT/i3N; (b and c) Commercial food grade TiO2 in di↵erent magnifications.
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The size and dispersion of these TiO2 particles were very similar to sub-/extracellular
structures that dissipate light in typical tissues. Actual biological tissues are more com-
plex than a homogeneous distribution of identical spherical particles or even randomly
shaped ones. A mixture of large and small particles may be a good approximation to de-
scribe tissue scattering properties. Figure 3.2 presents the di↵erence between the initial
stock PDMS and the turbid PDMS composite with about 0.142 % (w/w) of the synthesised
TiO2.
(a) Stock PDMS (b) Scattering PDMS
Figure 3.2: Photographs of mould casted PDMS slabs prepared with and without added
scattering agents.
Once a uniform distribution of the TiO2 powders into the PDMS matrix was achieved,
the optical characterization of the di↵erent PDMS slabs, made following a rigorous proto-
col such that the final thickness remained similar in all measured samples, was performed
and it is presented in the following section.
3.1.2 Optical characterization
Ultraviolet-visible (UV-Vis) spectra measured in transmission mode of each of the mould-
casted PDMS layers (Figure 3.2) are displayed in Figure 3.3. Confirming the transparency
of the stock PDMSmatrix in all the recorded spectrum (350-1500 nm) with the exceptions
of weak absorption peaks at around 1200 nm due to vibrations in the polyatomic CH3
groups in the PDMS [35]. The silicone matrix obtained using the Sylgard 184 kit presents
a very uniform group refractive index of about 1.4 (at a wavelength of 1.3µm) [34] very
close to common tissues. The extinction is however significantly increased with the
rise in the titania content thus, when the light passes through the film, it would be
more di cult for the photons to pass the di↵usive film. The central wavelength of the
clinical OCT systems in use ( OCT = 1350nm) is represented in the graph as a vertical
red line. At this wavelength the composite PDMS with a total weight percentage of 3 %
TiO2 has about twice the amount of the extinction of the 0.6 wt% phantom. As a result,
di↵erent magnitudes of scattering from each of the phantom are expected during the
OCT measurements. With this in mind, a multi-layered phantom was devised in order to
reproduce the structure of actual blood vessel walls.
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The blood vessels are divided into three layers [33] that are composed of di↵erent types
of cells:
• Intima, is the inner layer, mainly composed of endothelial cells has the middle OCT
signal;
• Media, is the middle layer, composed by connective tissue and smooth muscle cells,
has the lowest OCT signal ;
• Adventitia, is the outer layer, composed by fibrous tissue to provide support to the
artery. It has the highest OCT signal from all the three layers.
In this work only the two innermost layers (Intima and Media) were considered for the
phantom structure. The developed fabrication process only allowed the synthesis of
layers with about 1 mm (Figure 3.4) and the stacking of three di↵erent layers led to non-
malleable phantoms that were di cult to curve into the desired format for measurement
in the OCT system. In future procedures, if necessary, the phantoms could be constructed
with the help of a 3D printer, which would allow better control of the thickness of the
layers.
Figure 3.3: Extinction vs wavelength of stock PDMS substrate and of PDMS substrates
with di↵erent concentrations of TiO2 nanoparticles. Obtained without the cuvette on the
spectrometer: Substrate adhered to the stand (Approximate thickness of 1 mm).
Figure 3.4 represents the box plots with the variation of the thickness measurements of
each of the layers. The thickness measurements were performed using the image analysis
software ImageJ on the images obtained in the OCT systems, considering the pure PDMS
refractive index. On both of the layers the spacing between the di↵erent parts of the
box indicates some degree of dispersion of the measured thickness, which expresses an
heterogeneous thickness throughout the PDMS slabs.
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Figure 3.4: Thickness measurement distribution of each layer from optimized phantom.
Surface tension causes the sides of the phantom to curve contributing to the deviations
in the thickness measurement
In fact when observing the OCT cross-section of a phantom with both layers stacked
(Figure 3.16) smaller thickness of the intima and larger in the media are noticed on the
edges. This thickness distribution is mostly due to tensions with the mould during the
fabrication process. When the first layer is poured and spread the surface tension with
the mold walls creates a receding contact angle which when cured creates a protrusion in
the slabs (Figure 3.4-A). In turn, when the second layer is transfered the inverse inprint
occurs (Figure 3.4-B). This features in the phantom lead to the overall variations in the
measured thickness.
3.1.3 Synthesis and characterization of contrast agents
The synthesised gold nanostars where optically and morphologically characterized. Fig-
ure 3.5 shows the UV-Vis spectra of the 15 nm gold nano seeds (blue) used in the synthesis
of the gold nanostars whose spectra is observed in red.
Extensive literature is found on both the synthesis and optical characteristics of gold
nanostars [36, 37]. In all this reports two di↵erent localized surface plasmon ressonance
(LSPR) modes are described, corresponding to di↵erent locations of the near electric
field in the nanoparticles (central core (seed) and tips). Surface plasmons (SP), which
involve collective oscillations of electrons confined to a metal/dielectric boundary, can
interact strongly with incident electromagnetic fields [38]. Their behavior is directly
influenced by several parameters including the structure, shape, and size. This ultimately
a↵ects the optical properties of the nanoparticle, which can be observed via its UV-Visible
absorption.
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Figure 3.5: Extinction spectra of the Au nanoparticle seeds and following gold nanostars
from 380 - 1400 nm.
The prepared gold nanostars (GNST) display a well defined plasmon band with a maxi-
mum absorbance at 810 nm (tip mode), together with a weaker shoulder around 555 nm
corresponding to the core mode as shown in Figure 3.5. The GNST seeds have only one
band as expected at around 555 nm. The e↵ect of the tip mode LSPR presents interest-
ing possibilities as a large enhancement of the electric near field and light concentration
occurs near this wavelength. A so-called "antenna e↵ect"[39]. Moreover, a study by Abhi-
tosh Kedia and Pandian Senthil Kumar [36], showed that is also possible to precisely tune
the gold nanostars LSPR peaks by controlling the shape of the tips. Sharper tips lead to
an enhanced red-shift of the tip mode LSPR (Annex III.1 ) which can then be tuned to a
region near the central wavelength of the OCT imaging where a very strong interaction
occurs, enhancing the backscattered light.
Moreover, UV-Vis spectra of the GNST allowed to obtain their concentration in the
measured solution. At a wavelength of 400 nm organicmolecules and the surface plasmon
resonance of the gold nanoparticles have only minor influence. The absorbance is mainly
due to interband transitions of gold and therefore can serve as a robust measure of the
concentration [40]. As so, using the Beer-lambert law the concentration of an absorbing
species can be related to the absorbance (Abs400), as it has a linear relationship (Equation
3.1) [41].
Abs400 = " ⇥L⇥C (3.1)
Where " is the extinction coe cient (M 1cm 1), L is the optical path in cm, and C the
concentration in molarity. Assuming that a extinction of 1.2 at 400 nm corresponds to a
complete gold reduction (C = 0.5 mM) [42] and that the optical path corresponds to 1 cm,
the extinction coe cient of gold nanoparticles (" = 2.4⇥103M 1cm 1) is initially obtained.
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From here on, using the same equation, the calculation of the molar concentration of
the GNST was possible to attain. This values are then used in conjunction with the
morphology characteristics to obtain the value of particles/ml.
The morphological characterization by transmission electron microscopy is shown in
Figure 3.6. The images were analyzed using Image J and the diameter of the gold nanos-
tars was measured. For that, in image containing several GNSTs (> 100 particles), an
automated algorithm was used to draw an elipse around each star and the diameter was
measured. The obtained distribution is shown in Figure 3.6 for two di↵erent batches,
named SA56 and MC01.
Figure 3.6: TEM images of MC01 batch of gold nanostars. Diameter distribution for
MC01 (58± 19 nm) and SA56 (53± 9 nm) samples.
The GNST appeared to be relatively monodispersed with a mean diameter of 58 nm
(MC01). As an example of the variation during the synthesis process of the GNST, the
size distribution of a diferent batch of GNST is presented (SA56). Even though the exact
procedure was done in both batches a slight variation in size is observed.
Table 3.1: GNST morphological characterization and particle count.
Sample Mean Diameter [nm] Concentration [mM] Particles/mL
MC01 58.58± 19.46 0.302 3.9⇥1010
SA51 53.25± 9.78 0.555 7.2⇥1010
The ensuing analysis refers to Figure 3.7 where the recorded fluorescence emission of
the nile blue dye, adsorbed to the GNST surface, is present. A laser scanning microscope
was used both for the fluorescence characterization of the coded GNST, characterizing
it’s spectral emission properties, and the spatial mapping of said nanoparticles in further
functionalization studies. The inset in Figure 3.7 represents the confocal fluorescence
maps under illumination with a 633 nm laser. In each pixel of the fluorescence confocal
image, the emission spectrum was recorded using the lambda mode of the microscope.
In Figure 3.7 the integrated spectral information associated to the delineated region in
the recorded image are shown in the spectral range of 400 nm to 750 nm.
18
3.2. FUNCTIONALIZATION
Figure 3.7: Emission spectra of Nile blue dye at 5% power of a 633 nm laser.
3.2 Functionalization
3.2.1 Immobilization of GNST on the surface of PDMS
The silanization of glass substrates for the immobilization of gold nanoparticles has
been for a while an e cient method of creating platforms for photonic devices, micro-
electronics and biosensing [31]. In this, the well-established interaction between negatively-
charged gold colloids with ionic double layer and the positively-charged amino groups
is exploited. Coupling agents like amine-terminated silanes, link the inert glass and
colloid gold nanoparticles using this interactions. In this work the same immobilization
technique is applied to PDMS substrates. The entire procedure is represented in Figure
3.8. A selected region in the surface of the PDMS phantom was initially treated under an
oxygen plasma in order replace the silane (Si–CH2) groups with silanol (Si–OH) groups,
which can then react with one end of the selected amine-terminated silane.
Figure 3.8: Schematic of the GNST immobilization process. Image designed in Adobe
Illustrator and MolView®.
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The activation of the exposed PDMS surface creates a hydrophilic surface which al-
lowed to easily evaluate if the used mask managed to create two di↵erent sections in
the phantom. The PDMS is then immersed into the silane solution, where two di↵erent
immersion times were tested (5 and 15 min). This step was crucial for the following depo-
sition of the GNSTs, since for immersion times over 5 min no nanoparticles managed to
get attached. To confirm the deposition of the GNST, a confocal fluorescence microscope
was used to detect the nile blue coated GNST.
A confocal fluorescencemicroscopy image of the resulting un-/functionalized surface of
the PDMS is present bellow (Figure 3.9). This results were obtained after the optimization
of the GNST immobilization using an ethanol solution with 8.33%(V/V) APTMS silane.
Three di↵erent channels were used when analyzing the samples. A transmission channel
obtained through a transmission camera in the setup. A second reflection channel set
to detect any reflected light from the sample with the same wavelength as the laser in
use. And finally a fluorescence channel which detects the wavelengths that compose the
nile blue emission spectrum (Figure 3.7). In a confocal setup the reflection channel was
used to make sure that the fluorescence signal was indeed coming from the surface of the
PDMS, since the majority of the reflection of the used laser is at this interface between
the two di↵erent materials (air/PDMS).
Figure 3.9: Confocal microscope images of functionalized stock PDMS. A)Transmission
image, B) Reflection image, C) Transmission plus fluorescence.
In Figure 3.9-C an interface is clearly visible between a region where the fluorescence
signal is null (covered side) and a side where the GNST are evenly distributed trough the
surface. Following, the same process was preformed for the scattering PDMS slabs and
the results are presented bellow (Figure 3.10). Although the successful padronization
was also achieved in this substrates another e↵ect was noticeable. The GNST accumulate
in certain regions of the phantom which leads to the clusters observed in the fluorescence
image. This result is believed to be due to the added titania nanoparticles in the PDMS
matrix which create porous-like structures that trap GNST. Furthermore two di↵erent
silane reagents were used for the immobilization technique APTMS and APTES. Initially
the plan was to follow the procedure reported by Nguyen Ba Trung, et al. [31] were a
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Figure 3.10: Confocalmicroscope images of functionalized scattering PDMS (TiO2 PDMS).
A)Transmission image,B) Reflection image, C)Reflection plus fluorescence
1%(v/v) APTES solution is used to obtain the best results. However at the beginning of
this work such reagent was not available thus the similar silane molecule APTMS as used.
Yet to obtain obtain the same results the final concentration of APTMS (8.33 %(v/v))
had to be higher than the reported for APTES. The results using APTES (with the exact
procedure as reported in [31]) are presented in the annex IV, showing an even more
uniform immobilization of the GNST.
3.2.2 Biofunctionalization
In order to fully assemble the VeVo MicroMarker target-ready microbubbles, secondary
antibodies had to be initially biotinylated to facilitate the immobilization with the strep-
tavidin in the surface of the MB (Figure II.1). This process was done with the aid of
a biotinylation reagent from Thermo Scientific (EZ-Link Sulfo-NHS-LC-Biotin (lot nr.
21335, MW: 556.59)) which allows the the direct labeling of antibodies, or any other
biomolecules which contain free amine groups. The EZ-link user guide was followed in
order to accomplish the best possible results.
Initially to obtain an acceptable level of incorporation of the biotin in a dilute solution
of antibodies a greater fold molar excess of biotin reagent was accounted for. The user
guide referred a 50-fold molar excess of biotin to label 50-200 µg in 200-700 µl of bu↵er
and considering that the antibody solution in use was even more diluted (250µg of Ab in
3.750 mL) a 60-fold molar excess of biotin reagent was considered as a better approach.
After the correct amount of biotin reagent was determined and the labeling process was
performed a process of desalting or dialysis had to be devised in order to remove excess
non-reacted and hydrolyzed biotin reagent that remained in the solution. A number of
dialysis membranes and size-exclusion resins were studied for this process however they
did not present the resolution required for the e cient separation of the small molecules
of biotin, neither an e↵ective way to obtain high sample recoveries. As so, diafiltration
devices that featured high-molecular weight cut-o↵s (MWCO) were the opted solution.
This devices havemicro-molecule permeable filters with the correctMWCO that separates
immunoglobulins (>150kDa) from small proteins, peptides and even vitamins such as
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Biotin (244Da).
Additionally, in order to assess if the biotinylation process actually worked, the quan-
tification of the IgG/Biotin concentration was carried out comparing the absorbance at
280 nm with a standard BSA calibration curve whose concentration is known.
This way, di↵erences in the biotin concentration from the beginning of the process
when compared with the filtered un-reacted biotin could indicate the e ciency of the
process.
As so, during the filtration process aliquots of 15µL from di↵erent phases where kept in
a separate container and labeled for the protein quantification. Namely aliquots from the
initial biotin solution, the initial antibody solution, the solution with the antibodies and
biotin right after the labeling process, the concentrated solution (kept in by the permeable
filters), and finally the filtered solution which should in principle only be composed of
the small un-reacted biotin molecules that cross the filtration membranes.
The results of the BSA standard calibration curve and the subsequent quantification
are presented in the Annex V and the following table (Table 3.2).
Table 3.2: Protein absorption quantification.
Abs280 Concentration [mg/mL] Initial Volume [mL] Total Concentration/Expected [mg]
Initial Biotin solution 2.2 5.3 0.5 2.7 / 2.78
Initial antibody solution 0.1 0.2 3.75 0.7 / 0.25
Antibody + Biotin 0.3 0.8 3.76 2.9 / 3.03
Concentrated 0.04 0.1 0.3 0.04 / 0.02
Filtered 0.2 0.5 0.45 0.23 / 0.06
Altough biotin on its own doesn’t have absorption at the UV range (280 nm) [43] the
amine-reactive group used to couple with the antibodies does [44], allowing us to use the
absorption for the biotin quantification.
Upon analyzing the results in fact a reduction in biotin concentration was obtained
from the initial biotin solution to the filtered solution. Which entails that some portion of
the biotin molecules remained attached with the antibodies, successfully functionalizing
them.
Using the initial volume of each of the tested solutions the total concentration was
also calculated and compared with the quantity expected for the respective volume. In
the case of the initial antibody and the filtered solution an excessive amount was clearly
noticeable, even greater than the expected. This is believed to be from residual protein
which interfere in the consecutive measurements. This errors could have been avoided
by properly washing the detector each time a measure was taken. However in the case of
the concentrated solution the excess (0.02 mg) is most likely linked to the added biotin
groups adhered to the antibodies. This di↵erence was then used to find that there are an
estimated 270 biotin groups per antibody. However this di↵erence could still be due to
residual proteins in the detector, therefore to obtain a very accurate protein concentration
estimation another method should be considered e.g. the bradford method.
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3.3 Optical coherence tomography
One series of scattering and nonabsorbing phantoms was initially compared with stock
PDMS (transparent matrix material, without introducing scattering nanoparticles).
The samples were imaged using a clinical IV-OCT system and the results are shown
in Figure 3.12. Each image was selected from an cylindrical dataset (coaxial to the OCT
catheter) resultant of an OCT pullback. For this initial measurements, the malleable
phantoms were curved and put inside an eppendorf in a way that resembled the arteries
morphology (Figure 3.11).
Figure 3.11: Schematics of the tissue phantom imaging. A controlled amount of the
nanoprobe solution is put on a small area of the phantom. The phantom is curved
(nanoprobe area inside); and put inside an Eppendorf with water. Image designed in
Adobe Illustrator®.
At first, a calibration OCT pullback is performed in the same medium as subsequent
images in order to correctly calibrate the software measurements based on the known
diameter of the image catheter. Figure 3.12-A corresponds to said calibration in water,
where poor contrast is observed due to the low intensity of scattering. However, a signifi-
cant di↵erence is observed between the stock PDMS matrix (Figure 3.12 B,D,F) and the
scattering phantoms (Figure 3.12 C,E,G). As expected, the clear PDMS did not provide
any signal inside it’s matrix. These results can be explained from the extinction spectra
of the PDMS substrates(Figure 3.3). Almost all of the light is transmitted at 1350 nm in
the stock PDMS. Therefore it wasn’t expected any observable features in the phantom as
none of the light is being scattered back to the catheter. Only the edges of the phantom
are clearly observed due to optical reflection from the interface as light encounters a
refractive index change.
Contrarily, the phantoms with embedded TiO2 particles presented an almost continu-
ous bright background. Each of the titania nanoparticles/aggregates contributes to the
scattering in the PDMS matrix. Moreover, the intensity of the backscattered light drops
with penetration depth. After a certain depth, all light is mostly extinct from the path
inside the phantom and the intensity of the backscattered light significantly reduces. As
a result, the walls of the eppendorf, clearly visible in all stock PDMS images, become
very faint. The internal structure of the phantom is vastly homogenous with negligible
particle clusters.
The main goal of this work was to show the usefulness of each of the contrast agents,
for this reason, a drop with a controlled amount of the contrast agents in test (GNST and
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MB) was placed in the surface of the phantoms to observe their characteristic OCT signal.
After careful visual inspection, it can be observed that the OCT image displays significant
variation in intensity of backscattered light in specific regions of it’s surface.
Figure 3.12: Phantom study of the contrast agents (MB: Microbubbles and GNST: Gold
nanostars) for OCT. (A) Eppendorf full of water; (B) PDMS stock phantom in water; (C)
PDMS phantom with dispersed TiO2 (10 mg) - Scatterer; (D) PDMS stock with dried MB
spot on the surface; (E) Scatterer PDMS with dried MB spot on the surface; (F) PDMS
stock with dried GNST spot on the surface and respective “shadow e↵ect”; (G) Scatterer
PDMS with with dried GNST spot.
The synthesised Gold nanostars (Figure 3.12 F,G) produced a very faint contrast in the
PDMS phantoms. Notice the regions demarcated by the dashed line where the GNST
are present. While GNST of this size were believed to be relatively good absorbers of
near-infrared light (Figure 3.5), they did not appeared as e cient scatterers. The used
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branched gold nanoparticles (GNST) may not have a suitable mean size; as it has been
mentioned the shift in size/shape of the GNST brings significant changes in the peak
position of tip/core mode plasmons. These resonance bands when close to the central
sources used for OCT imaging (central wavelength) produce a very strong interaction,
enhancing the backscattered light [45]. However this is not the case, the peak of the tip
mode LSPR is at about 810 nm while the central wavelength of this particular clinical
IV-OCT is at 1350 nm. As was shown above, one of the ways to obtain e↵ective contrast
agents for imaging would then be to increase the mean diameter of the GNST.
However, the increase in size of the nanoparticles brings some pathological concerns in
the biological environment that need to be taken in account due to potential health risk.
Tough gold nanoparticles are recognized as bio-safe materials and currently researched
for biomedical applications such as imaging and targeted drug delivery, studies in mice
have revealed that the size plays an important role in their pathological e↵ects on di↵erent
organs [46]. In the work by Tianmeng Sun, Rachel Simmons, et al. [47] the study of the
bio distribution of di↵erent size gold nanoparticles was performed. It revealed that
nanoparticles with a size greater than 5 nm mostly accumulated in the spleen and liver.
This organs, from the reticuloendothelial system are responsible for rapid removal of the
particles from circulation and are one of the physiological barriers that limits the journey
of the nanoparticles [48]. However, in this organs, significant pathological changes to
their architecture where reported [46], preventing them from being recognized as safe
for intervascular contrast agents.
On the whole, gold nanostars are an obvious choice due to their amenability of synthesis
and functionalization, yet they are not good for OCT at this wavelength and not for
human use. Therefore, e↵orts shifted to a di↵erent type of contrast agents, the PBCA
microbubbles.
Figure 3.13: Profile of double layer phantoms. Two profile plots are represented. One of
the regular phantom (A-scan 1) the other in a region with MB (A-scan 2).
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A drop containing 2.8µm microbubbles was placed in the surface of the phantom as
shown in Figure 3.11. Notice the di↵erence between the regions of the phantom in Figure
3.12-(E). A microbubble (MB) layer appears as a highly scattering line, creating a shadow.
The signal provided by the microbubbles has a dual characteristic (creates a shadow and
shows high reflectivity) that allows its unequivocal location in the sample. In order to
further visualize the characteristic signal of the microbubbles, two distinct A-scans from
Figure 3.12 were analyzed in Figure 3.13. The gray values were obtained radially to
center of the OCT images until a distance of 5 mm from the catheter. The initial gray
value peaks, identical in both profiles, correspond to the profile of the imaging catheter.
From a region starting 0.5 mm to 2.5 mm the di↵erences are then clearly visible between
the normal phantom (A-scan 1) and a region where the MB are present (A-scan 2).
In the phantom the scattering decays constantly due to the extinction of the light
beam as the imaging depth increases. The noise observed in the graph is referred to as
speckle noise and is characteristic to all coherent imaging systems. It is caused by the
interference of light scattered from multiple points within the turbid phantom [49]. On
the other hand, the profile obtained in the region with microbubbles presents a di↵erent
scenario. A narrow high intensity peak is observed followed by an exponential decay of
the gray values. This “hypersignal” given by the 2.8µm microbubbles arises from the
refractive index mismatch between the gas-filled MB and the surrounding medium. As
the refractive index mismatches increase the scattering increases.
In light of the drawbacks presented for the GNST, microbubbles [MB; currently U. S.
Food and Drug Administration (FDA) approved intravascular contrast agents in diagnos-
tic ultrasound [27]] may be a great alternative contrast agent. No other structure in OCT
imaging appears has the “shadowed” signal presented by these layer of microbubbles.
The only relatable behaviour is that from the struts of a stent that are distributed homoge-
neously and lie against the intima. In this case the high reflection of the OCT light beam
is due to the metal struts, which also cast strong shadows dorsally (Figure 3.14).
Figure 3.14: OCT cross-section of a stented artery section. Adapted from OCT Com-
pendium by Holger Nef and Albrecht Elsãsser [50] and Science Picture Co stock photos.
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Following, a Matlab script was created so that the cylindrical dataset resultant of each
OCT pullback could be analyzed in its whole. As so, each of the radial images that com-
poses this dataset was initially individually “unwrapped” e.g. The input RGB color image
(cartesian space) is converted to 16-bit grayscale and remaped with polar coordinates.
The remaped images correspond to the set of radial A-scans that compose the image for
each angle (1º to 360º) (Figure 3.15-B). For a given remaped image the intensity values
along each A-scan are summed. The results are then plotted for all the slices of the OCT
pullback. The outcome e↵ectively projects the attenuation and backscatter in a “carpet
view” of the entire sample (Figure 3.15-C)
Figure 3.15: a) OCT cross-section of a initial optical phantom were MB contrast is visible,
followed by b) the respective unwrapped image and the c) carpet view from all the cross-
section taken in the OCT pull-back.
The placement and shape of the drop of MB is then clearly visible as a region where the
total intensity value is lower than the surrounding area. This reflects the entire portion
that is “shadowed” dorsally to the MB layer. Although the overall shape of the drop is
that of a circle, certain regions within this shape have di↵erent gray value intensities.
This is due to the heterogeneous distribution of the MBs. Denser areas, where the MB
are largely accumulated cast an intense shadow since light is more e ciently scattered.
Whereas areas less populated still allow some of the light to pass trough. This result has
important implications such as the limit of detection of di↵erent MB concentrations.
Therefore some tests were carried out trying to vary the total amount of MB in a con-
trolled area. Squares with 0.5 cm side, placed at an equal distance from each other (0.5
cm), were delimited using duct tape. The tape served as a mask for the later N2 plasma
activation of the PDMS surface. The exposed surface then became hydrophilic unlike the
remaining PDMS. This step was performed in hopes of containing the MB solution drop
in the stipulated area.
Three di↵erent quantities of MB were used. Initially the amount of 2µm MB to cover
the (0.5cm)2 surface was calculated: ⇡ 6.25⇥ 106 MB. It was then defined that from the
stock MB solution (3.3 ⇥ 109 MB/mL) 2µL where going to be used in the first square
(6.6⇥ 106 MB). From here on the stock solution was sequentially diluted. The following
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square had the stock solution diluted in Triton in a ratio of 1:4, from this 2 µL were used
(1.65⇥ 106 MB). The late solution was again diluted 10-fold (1:40 of the stock solution)
and 2µL where removed (1.65 ⇥ 105 MB). Each of the MB solutions was placed in the
respective square and left to dry while the entire PDMS slab was oscillating in a lab
shaker. This step was carried out in order to achieve an homogeneous distribution of
the MB throughout the specified area. The optimized double layer phantom referred in
Section 3.1.2 was also used in this tests. The OCT images and their respective treatment
are present in Figure 3.16.
Figure 3.16: OCT cross-section of a double PDMS layer optical phantom with MB shad-
owing e↵ect, followed by the respective unwrapped image and the carpet view from all
the cross-section taken in the OCT pull-back.
Even tough preventive steps were taken to assure a better distribution of the MB in
the required area, the visual inspection of the “carpet view” of the sample indicates the
clustering of the MB. The inset in Figure 3.16 represents one of the sample areas where
the MB were deposited. Most likely correspondent to the stock solution (6.6 ⇥ 106 MB)
since the MB deposition was performed sequentially from the most concentrated to the
less concentrated. Furthermore, no other “shadowed” regions where visible throughout
the sample.
The MB as in the immobilization of the GNST in section 3.2.1 should have been func-
tionalized with the surface of the PDMS. In fact some strategies for the immobilization
of the MB in the PDMS surface were considered and even tested. One of this options
was the MB-shell functionalization process reported by P. Koczera et al. [30]. In their
work the MB are coupled with streptavidin using EDC (i.e N-(3-dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride) coupling chemistry. This process is the most common
technique for the labeling and crosslinking of carboxylic acids to primary amines [51].
With this in mind, the idea was to use EDC chemistry in order to crosslink the MB with
the primary amine of the silanized PDMS used in the GNST immobilization (Section
3.2.1). However, following the method described by P. Koczera et al. the MB solution
had to be initially partly hydrolyzed by increasing the pH to around 10, which in the
28
3.3. OPTICAL COHERENCE TOMOGRAPHY
tests performed in this work always lead to the instability of the MB and their dissolution.
This is believed to be mostly due to the lack of precise methods to tune the pH, which
leads to the rapid variation of the values. Thus, without the successful hydrolyzation the
butyl-ester groups of the PBCA side chains no resulting carboxyl groups were available
for the following EDC process and the immobilization of the MB was not attained.
Figure 3.17: Normal coronary artery.
Adapted from: OCT Compendium by
Holger Nef and Albrecht Elsãsser [50]
Nonetheless the evaluation of the opti-
mized double layer phantom was still per-
formed. In a brief comparison of a OCT im-
age of the devised phantom (Figure 3.16)
with one of a normal coronary artery (Fig-
ure 3.17) the similarities are clearly visible.
In both images the layers are easily distin-
guished by di↵erent scattering intensities
and the overall shape fits the radial pro-
file of a normal artery. Furthermore, two
A-scans from the double layer phantom
where recorded from a region with and
without MB and the results are present in
Annex VI.
To evaluate the e↵ects of microbubbles on OCT images of blood vessels, post mortem
human carotids were imaged with OCT. Using an optimized method for OCT image
acquisition (Figure 3.18) the sectioned arteries where fixed in position allowing for a
undisturbed OCT pullback.
Figure 3.18: OCT setup allowing the fix of both phantoms and arteries while testing.
Image designed in Adobe Illustrator®and draw.io [Browser-based end-user diagramming
application] (2019).
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One of the sections of the artery was incubated with the Target-Ready microbubbles
that had been functionalized with anti-VE-Cadherin IgG antibodies and was referred
as the positive control (+MB). While the negative control was only immersed in a PBS
blocking solution.
Vascular endothelial - cadherin (VE-CAD), also called 7B4 and cadherin-5, belongs to
the class of cell adhesion molecules called cadherins [52]. Cadherins play a role in tissue
formation and help maintain tissue architecture in the adult [53]. VE-cadherin, more
specifically is located at endothelial junctions [54], and was chosen precisely because of
this location. The endothelial cells line the interior surface of blood vessels and biomark-
ers in this region would provide the closest comparison with the tests in the phantom
samples. Furthermore, the endothelial lining is involved in inflammatory responses as
in the case of atherosclerosis [55]. The arteries used in this work had been previously
confirmed for the presence of the endothelial cells in a immunohistochemistry process
performed by the group at INL. A selected OCT image and the respective remapping is
present in Figure 3.19.
Figure 3.19: OCT cross-section and respective unwraped image of two sections of human
carotid artery. +MB: Artery section incubated with targeted MB; -MB: artery section
incubated in blocking solution; S: separation between the two artery sections.
For the morphological analysis of the OCT Scan the principles of interpretation of such
exams can be applied. As so, some steps are usually undertaken in order to obtain the
best classification scheme. Initially one should inquire if there are any abnormalities in
the vessel walls. Which besides the region where both sections of the artery are separated
only irregular reflection and attenuation profiles are noticed in the +MB. Following,
analyzing the brightness and the shadows it is possible to guess the type of tissue and the
structures. In the -MB section no shadows, bright areas or dark spots are visible which is
30
3.3. OPTICAL COHERENCE TOMOGRAPHY
correspondent to the normal signal of a vessel wall.
However, in the artery section where the MB were incubated the signal appears to be
heterogeneous. Some regions exhibit thin bright bands at the surface facing the OCT
catheter followed by pronounced shadows. This type of profiles are usually associated
either to stents or thrombus regions (Table 3.3). Yet, none of this structures could have
been present in the samples as so it is assumed that these are regions where MB have
successfully binded with endothelial biomarkers. In fact the MB shadowing e↵ect and
hypersignal reported before is clearly visible.
Table 3.3: Identification of the tissue and the structures using reflection and attenuation.
Adatpted from: OCT Compendium by Holger Nef and Albrecht Elsãsser [50]
Reflection and
attenuation
Strong reflection
(bright area)
Weak reflection
(dark area)
Strong attenuation
(strong shadows)
Bright area, strong shadows,
e.g. stent, red thrombus
Stent: Attenuation due
to reflection and absorption
Thrombus: Attenuation due
to reflection and absorption
Dark area, strong shadows,
e.g. lipid
Attenuation due to absorption
Weak attenuation
(weak shadows)
Bright area, hardly any shadows,
e.g. fibrous tissue
Dark area, hardly any shadows,
e.g. plaque
The “carpet view” of the OCT pullback was obtained using the designed MATLAB
script and is represented in Figure 3.20 side by side with a picture of the respective artery
sections. The location of the cross-section in Figure 3.19 is represented by the yellow
line in the “carpet view”. Furthermore, the regions that corresponded to the behaviour
described above (Strong shadows and bright area) are delimited by a white dashed line.
Figure 3.20: Carpet view from the artery sections OCT pull-back. -MB: Artery section
incubated with targeted MB; -MB: artery section incubated in blocking solution; Ar:
Artifact
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The e↵ect of the MB is substantial, the region where they are present is able to be
easily distinguished from the surrounding tissue. Only some image artifacts from the
OCT catheter leaning against the artery walls create darkened spots that can be easily
dismissed by observing the respective cross-sections at the given pullback length.
However having used MB targeted for endothelial cells one might ask why are the
MB confined to certain regions and not the entire lining of the artery. The thing is that
investigation of the endothelial layer may be hampered since it is a very fragile structure
that can be destroyed trough all the handling steps of the sample. Leaving only small
sections of endothelial cells.
Advances in MB functionalization can enable the incorporation of various targeting
ligands. Instead of general VE-cadherin endothelial biomarker, specific targets that reflect
vulnerable plaque progression can be used to track the disease. As a matter of fact a whole
research area is dedicated solely into understanding which molecular medical signs are
unique to vulnerable plaques [56].
Focal manifestations of atherosclerosis such as inflammation and endothelial activation
are potentially the most direct approach to disease biomarkers. As so, biomarkers for pro-
inflammatory cytokines (IL-6, IL-1 , TNF-↵) and acute-phase reactants (CRP, PTX3) or
even cell adhesion molecules (ICAM-1, VCAM-1, E-Selectin) [56, 57] would be candidates
for future targeted MB.
The otherwise poor personalized risk assessment and guided treatment [58] could then
be mitigated by an accurate vulnerable plaque location and quantification. In fact one
of the main advantages of the MB referred by the partner physicians in both Braga and
Vigo Hospital would be in guiding interventional procedures such as stent placement.
Pre-emptively increasing the stented region into surrounding vulnerable plaques (when
present) could potentially reduce the risk of stent-caused acute cases from induced strains.
This is an example of a risk-factor–reducing strategy that can be implemented with vul-
nerable plaque prediction.
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Chapter 4
Conclusion and Future Perspectives
The ability to survey the distribution of a biochemical species within a biological sample
provides an essential dimension of information beyond the tissue morphology obtained in
current optical coherence tomography setups. However, as a first step, molecular-specific
exogenous contrast agents needed to be identified and investigated. Doing so, some of
the pertinent questions in the field were addressed in this work: (1) Can contrast agents
be easily prototyped before being tested in actual living tissues? (2) How do we engineer
some of the contrast agents to optimize on their contrast rendering capability? (3) How
do we functionalize the contrast agents so that they can bind to a biochemical species of
interest?
In this study we find a faint increase in intensity of the OCT signal in areas containing
GNST. Showing that gold nanostar-shaped nanoparticles where not the best option for
OCT imaging as size limitations eliminate the possibility of tuning the LSPR peaks into
the working wavelength ofmost clinical OCTs without consequent pathological e↵ects. As
so, in order to obtain plasmon-resonant contrast agents, more e cient structures or even
di↵erent materials should be investigated to obtain an increased scattering e↵ect at the
working wavelength of most OCT systems (⇡ 1300nm) without significantly increasing
their size.
The gold nanoparticles were however successfully immobilized and patterned in the de-
signed tissue-mimicking phantom. A process that could be of great importance in testing
di↵erent types of contrast agents, allowing a case-by-case study of their qualitative signal
as a marker for the expression of surface receptors without the di culty of constantly
arranging post mortem arteries that aren’t always available and that require a lot more
preparation.
Conversely, it is suggested that targeted-microbubbles are interesting candidates for
increasing sensitivity in OCT diagnosis of vulnerable plaques because MB not only sig-
nificantly enhance OCT contrast but provide an unequivocal signal from all di↵erent
types of structures in human arteries. Moreover, the fact that this type of contrast agent
is already approved for intervascular use in ultrasound imaging techniques facilitates
its adaptation to this new type of modality. Each imaging method di↵ers from another
in terms of resolution, imaging depth and sample intrusiveness. As so, on many occa-
sions it is important to complement prognosis with di↵erent imaging modalities. The
development of multimodal contrast agents such as the presented PBCA microbubbles is
therefore considered to be highly advantageous in improving patient care and reducing
the number of contrast agents administrations. This should encourage future trials ex-
ploring not only diagnostic accuracy of MB in OCT imaging but also look into the specific
molecular targets to be functionalized on their surface.
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Future perspectives
A further research objective will include the optimization of the imaging protocol for
the post mortem human arteries by adding pre and post microbbubble contrast agent
incubation images which should allow to unambiguously associate the signal to the MB
and not any other structures or image artifacts.
Further detailed characterisation of the microbbubles will be gained by continuous
analysis of samples, namely the limits of detection using OCT, varying the di↵erent con-
centrations of microbubbles especially if the successfull Phantom PDMS immobilization
of this contrast agents is attained. The PDMS immobilization will allow for faster and
more precise quantification of the microbbuble signal using OCT.
The initial testing of di↵erent biomarkers attached to theMB, more specific to atheroscle-
rotic process should also be taken into consideration. Biomarkers such as the referred
pro-inflammatory cytokines (IL-6, IL-1, TNF-) and acute-phase reactants (CRP, PTX3) or
even cell adhesion molecules (ICAM-1, VCAM-1, E-Selectin).
Furthermore, the antibody tomicrobbuble functionalization process, based in the biotin
streptavidin interaction, should also be reviewed since actual in vivo application would
most certainly lead to nonspecific antibody binding since streptavidin would bind to the
already present biotin in the human body.
Finally the creation of a lumen segmentation algorithm, that would delimit the profile
of the artery walls, could be used to further perfect the MATLab script created for the
projection of the artery pull back. In turn, allowing for a increase in the “carpet view”
(3D view of the artery) contrast in regions with microbbubbles, since it would allow for a
better control over the sections being summed to obtain this image.
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Annex I
Nanostars synthesis
Citrate stabilized gold nanoparticles will be synthesized by using the Turkevich method
[29].
Reagents:
• Aqua regia – for glassware cleaning (1 Volume of nitric acid (HNO3) and 3 volumes
of hydrochloric acid (3HCl) are mixed).
• HAuCl4 x 3H2O
• Sodium citrate dihydrate
• Milli-Q water
Procedure:
Gold citrate nanoparticles synthesis:
1. 100 mL of 0.5 mM aqueous solution of HAuCl4 under vigorous magnetic stirring
and heated boiling.
2. When the mixture from 1 is boiling, quickly add 5 mL of a 1% sodium citrate
solution (previously heated to avoid temperature decompensation). Keep heating
and stirring until the solution turns from light yellow to dark red (wine appearance).
3. Leave until it reaches room temperature and store in fridge.
4. Calculate the Au concentration with ABS400.
PVP coating of the gold citrate nanoparticles previously synthesized:
• PVP (M.W. 10000 g/mol): We have to coat the gold surface with 60 PVP molecules
per nm2 of gold citrate.
• Magnetic stirring overnight.
• Washing cycle 90 minutes/7000 rpm.
• Remove supernatant and repeat washing cycles of removed supernatant until it’s
transparent or almost transparent.
• Redisperse in EtOH or isopropanol. You can use the volume that you like to redis-
perse, but I usually redisperse again in the same starting volume.
• Recalculate the concentration of gold with UV-vis and ABS400.
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GNST synthesis:
Based on the reported work by Pandian Senthil Kumar et al 2008 Nanotechnology [28].
Reagents:
• Solvent: DMF
• PVP-10000= 10 mM
• HAuCl4= 0.5 mM
• Au-citrate-PVP= 0.8⇥ 10 3M GOLD SEEDS (Can change with new synthesis)
Procedure:
1. Dissolve the 10 g PVP in the 100 mL DMF
2. Sonicate 15 min.
3. Undermagnetic stirring add the 396.6 µLHAuCl4: (stock concentration=0.12608M)
wait around 2 minutes.
4. Undermagnetic stirring add the 3.13mL gold seeds coatedwith PVP (Au@Citrate@PVP,
stock concentration = 0.8⇥10 3 M) and wait 1h or until full reduction is observed –
UV-vis and blueish color
5. 3 washing cycles 30 min 4000/4000/4000.
6. Redisperse in isopropanol
7. After the washes (in 25 mL) the last one GNSTs are redispersed in half of the volume
(in 12.5 mL).
8. Measurement of the concentration by UV-Vis, ABS400.
GNST and fluorescent dye Codification
1. Put in a falcon 1 mL of GNST at 0.8 mM
+ add 2.7 µL MUA (Mercaptoundecanoic acid) (0.0375 mM) at final concentration
0.1µM
+ TB (Toluidine Blue) and NB (Nile Blue) in final concentration of the 10 4 M
+ add 4.3 µL of NH4OH 29%.
2. Magnetic stirring during 2h.
3. Washing step – centrifuge at 2500 rpm during 30 min, then remove the supernatant
and add IPA until 1 mL.
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MB biofunctionalization protocol
II.1 Biotin Labeling Reaction
1. Remove the vial of Sulfo-NHS-LC-Biotin from freezer and equilibrate it to room
temperature before opening
2. Immediately before use, prepare a 10 mM solution of the biotin reagent. Add 2.78
mg of reagent to 500µl of ultrapure water in a 0.5 mL eppendorf. Keep 15µl on a
200µl eppendorf and label.
3. Dilute 250µg of antibody stock solution in saline solution for a total volume of
3.750 mL. From the 2.5 mg/mL antibody stock remove 100µl and add to 3.65 mL
of saline. Keep 15µl on a 200µl eppendorf and label.
4. Add 10µl of Biotin (10 mM) to the protein solution
5. Incubate the reaction in ice for 2 hours or at room temperature for 30 min. Keep
15µl on a 200µl eppendorf and label.
6. Protein labeling is complete at this point, and although excess non-reacted and
hydrolyzed biotin reagent remains in the solution, it is often possible to perform
preliminary tests of the labeled protein by Elisa or Western blot. To use use the
biotinylated antibodies with the microbubbles the proteins first must be desalted
or dialyzed to remove non reacted biotin.
II.2 Antibody filtration
1. In one centrifugal filter add 500µL of the prepared protein solution.
2. Centrifuge for 10 min at 15k RPM, at room temperature.
3. For this filtering conditions, the Amicon centrifugal filter’s user refered that the
concentrate solution should have 50µL of 2/3 mg/mL of protein. Since for the
following steps it is required 20µg of antibody in a total volume of 300µL, 30µL
of the concentrate solution were added to 0.27 mL of saline.
II.3 Vevo MicroMarker Contrast Agent Conjugated with the
Isotype Control Antibody
1. Attach the 21G 5/8” needle to the 1 mL syringe
2. Reconstitute the Target-ready contrast agent from one of the vials by ejecting 0.7
mL of saline.
3. Gently agitate for 10 seconds and let sit at room temperature.
4. Using a 21G 5/8” needle with a 1 mL syringe draw up 0.3 mL of the biotinylated
antibody solution prepared before ( 20µg biotynilated-Ab in a total volume of
300µL saline solution). Inject it into the vial of reconstituted Vevo Marker. Total
volume 1000µl
5. Gently agitate the vial by hand for 1 min and let it rest at room temperature for 15
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minutes
Figure II.1: Lyophilized VeVo MicroMarker® stored in a glass vial. The vial contains a gas
head-space consisting of nitrogen (N2) and perfluorobutane (C4F10). Graphical represen-
tation of Non-targeted and Target-Ready surface-modified microbubbles (MB). Adapted
from "Discover Nonlinear Ultrasound Contrast Agent Imaging", FUJIFILM VisualSonics
website using Adobe Illustrator®.
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Nanostar shape
Figure III.1: Optical absorption spectra (centre) showing the e↵ect of the size/shape of
GNST in plasmon peak position [36]. The decrease of the GNST tips leads to weaker
plasmonic e↵ect and at lower wavelengths.
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Annex I V
GNST immobilization APTES
Figure IV.1: Confocal microscope images of functionalized stock PDMS. A)Transmission
image,B)Fluorescence image.
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Annex V
Biotin quantification
Table V.1: BSA concentration in saline solution versus respective absorbance values used
in the standard calibration curve.
BSA Concentration Measured absorbances
mg/mL Abs1 Abs2 Abs3 Average
A 250 103 105 105 104
B 125 43 45 44 44
C 62.5 23 36 23 27
D 31.3 4 12 23 13
E 15.6 2 3 2 2
F 7.8 1 2 1 1
G 3.9 1 1 1 1
H 0 0 0 0 0
Figure V.1: BSA calibration curve and respective linear fit.
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Table V.2: Measured absorbance of the di↵erent aliquots from the filtration process and
the respective interpolation of the concentration based on the calibration curve.
Measured absorbance Concentration
Abs1 Abs2 Abs3 Average mg/mL
Initial Biotin 2 3 1 2 5
Initial Antibody 0.08 0.06 0.07 0.07 0.18
Total antibody+biotin 0.30 0.32 0.31 0.31 0.77
Concentrated 0.03 0.04 0.05 0.04 0.12
Filtered 0.20 0.20 0.20 0.20 0.50
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OCT A-Scans
Figure VI.1: Raw profile of double layer phantoms. In profile A, a region without MB,
two distinct scattering profiles are noticed from the two layers with di↵erent TiO2 con-
centrations. The intensity decay is dissimilar between the layers.
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